Coming out soon
We have developed a machine learning and rule based tool called the Clinical Trial Risk Tool using natural language processing. The Clinical Trial Risk Tool allows a user to upload a trial protocol and which categorises the protocol as high, medium, or low risk of ending uninformatively.
When a pharmaceutical company develops a drug, it needs to pass through several phases of clinical trials before it can be approved by regulators.
Before the trial is run, the drug developer writes a document called a protocol. This contains key information about how long the trial will run for, what is the risk to participants, what kind of treatment is being investigated, etc.
The tool is open-source under MIT licence and it does not save any of your data.
Currently, professionals at a funding organisation read the protocols and perform a subjective assessment of the trial’s cost, complexity, and risk of ending uninformatively.
One of the most common causes of a trial ending uninformatively is underpowering. There are several indicators of high risk of uninformativeness which can be identified in a protocol, such as a lack of and or an inadequate statistical analysis plan, use of non-standard endpoints, or the use of cluster randomisation. Low-risk trials are often run by well-known institutions with external funding and an international or intercontinental array of sites. These indicators can be referred to as features or parameters.
If you would like to cite the tool alone, you can cite:
Wood TA and McNair D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness. Gates Open Res 2023, 7:56 doi: 10.12688/gatesopenres.14416.1.
A BibTeX entry for LaTeX users is
@article{Wood_2023,
doi = {10.12688/gatesopenres.14416.1},
url = {https://doi.org/10.12688%2Fgatesopenres.14416.1},
year = 2023,
month = {apr},
publisher = {F1000 Research Ltd},
volume = {7},
pages = {56},
author = {Thomas A Wood and Douglas McNair},
title = {Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness},
journal = {Gates Open Research}
}Blog
Clinical trial designs vary considerably, impacting study execution, patient recruitment, endpoints, and treatment delivery. Here’s a brief summary of some common designs: First-In-Human (FIH) Studies These are the initial human trials for a new drug, procedure, or treatment, focusing primarily on safety. Cohort Studies These observational studies follow a group of individuals over an extended period to assess risk factors associated with developing specific conditions. Case-Control Studies These studies compare individuals with a particular disease or condition (cases) to similar individuals without the disease (controls) to identify potential risk factors.
This post originally appeared on Fast Data Science’s blog on LinkedIn. The Growing Role of AI in Clinical Trials Clinical trials are vital for advancing medicine, but managing them efficiently is a constant challenge. Traditional methods for assessing risks and estimating costs often miss the mark, leading to delays and unexpected expenses. This is where Artificial Intelligence (AI) and Natural Language Processing (NLP) come into play, offering smarter, data-driven solutions to streamline trial planning and management.
This post originally appeared on Fast Data Science’s blog on LinkedIn. Budgeting is one of the most critical steps when planning a clinical trial. Clinical trials are complex, multi-phase studies that require significant resources, and understanding the costs associated with each phase is crucial for an accurate clinical trial budget. In this post, we’ll explore the different phases of clinical trials and the key factors that influence their costs, providing insights into how to prepare a comprehensive budget that aligns with your trial’s needs.